Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM,...
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply
read more
News
Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates...
Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity
Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June...
Registration for 2025 World Astatine Community Meeting Now Open
Radiopharmaceutical experts and researchers to gather June 19-20 in New OrleansNEW ORLEANS – May 12, 2025 – The...
Nusano to Participate in Radiopharma Supply Chain Panel at the 21st Annual PEGS Summit Boston
WEST VALLEY CITY, Utah – May 12, 2025 – Nusano, a physics company transforming the production of radioisotopes, today...
Nusano Names Rachel Culbertson VP of Supply Chain
WEST VALLEY CITY, Utah – April 30, 2025 – Nusano, a physics company transforming the production of radioisotopes,...
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates